Redhill Biopharma Ltd. (RDHL) News
Filter RDHL News Items
RDHL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RDHL News Highlights
- For RDHL, its 30 day story count is now at 2.
- Over the past 8 days, the trend for RDHL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest RDHL News From Around the Web
Below are the latest news stories about REDHILL BIOPHARMA LTD that investors may wish to consider to help them evaluate RDHL as an investment opportunity.
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its two novel, oral host-directed investigational drugs, opaganib[1] and RHB-107 (upamostat)[2], demonstrated robust synergistic effect when combined individually with remdesivir (Veklury®)[3], significantly improving viral inhibition while maintaining cell viability, in a new U.S. Army-funded and conducted Ebola virus in vitro study. |
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was requir |
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 StudyRedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study. |
Why Is ImmunoGen (IMGN) Stock Up 81% Today?ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal. |
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?Redhill Biopharma stock is falling on Thursday as shares of RDHL give up some of the gains they made throughout the week. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! |
5 Investors Betting Big on RedHill Biopharma (RDHL) StockAlthough incredibly risky, RedHill Biopharma skyrocketed on an FDA exclusivity grant, thus warranting another look at RDHL stock. |
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years' market exclusivity for Talicia3 under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by the FDA Exclusivity Board. This grant is on top of three years' exclusivity granted for the approval of Talicia under section 505(b)(2). Tal |